Introduction
============

The increasing application of cardiopulmonary bypass (CPB) technology has improved cardiovascular surgeries and significantly increased the survival rate of patients ([@b1-mmr-12-06-7859]). Despite the advantages of CPB, it causes damage to other body parts. Although numerous studies have explored means of reducing the damage of CPB to the body, which led to a significant improvement of the survival rate of patients and a reduction in the incidence of post-operative complications with regard to other organs, the incidence rate of neurological complications has remained relatively constant; for example, the incidence rates of stroke and encephalopathy following CPB are 2--5 and 10--30%, respectively ([@b2-mmr-12-06-7859]). The time of hospitalization of patients following CPB is increased in order to minimize the risk of brain damage and other complications, which leads to the consumption of medical resources and impedes the development of cardiovascular surgery.

The mechanisms of CPB-associated brain injury include cerebral artery embolization, hypoperfusion, cerebral metabolic disorders, inflammatory damage and ischemia/re-perfusion injury ([@b1-mmr-12-06-7859],[@b3-mmr-12-06-7859]). Among these, inflammatory damage is one of the hotspots of research regarding CPB-induced complications. Due to the combination of the patients\' immune-associated stress response and damage from surgical equipment and procedures during CPB, activation and release of cytokines as an initiation of the \'inflammatory cascade\' leads to systemic inflammatory response syndrome and brain injury. Therefore, mitigating inflammatory damage is an important aspect of cerebral protection during CPB. Bowen *et al* ([@b4-mmr-12-06-7859]) found that the prevention of the inflammatory reaction not only alleviates inflammation-associated damage but also induces the body\'s tolerance to ischemic brain injury.

Pradillo *et al* ([@b5-mmr-12-06-7859]) and Broad *et al* ([@b6-mmr-12-06-7859]) found that pre-excited Toll-like receptors (TLRs) can not only prevent the inflammatory reaction, but also decrease the area of cerebral ischemic infarct and increase the tolerance to brain injury. The TLR family ([@b7-mmr-12-06-7859]) is a group of recognition receptors of the immune response, which are highly expressed in the central nervous system. TLR3 has a particularly important role within the TLR family ([@b8-mmr-12-06-7859]); first of all, TLR3 is highly expressed in astrocytes; furthermore, there are two immune pathways downstream of the TLR family, including TLR2, 4, 8 and 9 ([@b9-mmr-12-06-7859],[@b10-mmr-12-06-7859]), which proceed via the MyD88 pathway, while only TLR3 solely relies on the TIR-domain-containing adapter-inducing interferon-β (TRIF)-dependent pathway. Pan *et al* ([@b11-mmr-12-06-7859]) proved that pre-excited TLR3 can increase the tolerance of brain tissue to ischemic injury and reduce the inflammatory reaction, while promoting the production of anti-inflammatory cytokines and neuroprotective mediators and reducing ischemic brain injury.

The implementation of neuroprotective strategies in the perioperative period can significantly reduce neurological complications after CPB ([@b12-mmr-12-06-7859]--[@b14-mmr-12-06-7859]). Apart from the inhibition of inflammation-induced damage, existing neuro-protective measures include the improvement of CPB devices and surgical techniques as well as ischemic pre-conditioning and the application of protective drugs ([@b15-mmr-12-06-7859]--[@b17-mmr-12-06-7859]). Protective drugs can be divided into classes including narcotics, suppressors of the inflammation reaction and neuroprotective agents. Anesthetic-induced pre-conditioning (APC) ([@b18-mmr-12-06-7859]) and ischemic preconditioning (IPC) ([@b19-mmr-12-06-7859]) have exactly the same mechanism of action, namely the non-noxious stimuli-adaptation/noxious stimuli-tolerance. The neuroprotective effects of sevoflurane amongst anesthetic drugs is one of the current research hotspots ([@b20-mmr-12-06-7859],[@b21-mmr-12-06-7859]).

As the inhalation of anesthetics is widely used in clinical cardiovascular surgery, the safety of sevoflurane ([@b22-mmr-12-06-7859]) has been confirmed. Studies have confirmed that sevoflurane has a protective effect against damage to the nervous system ([@b22-mmr-12-06-7859],[@b23-mmr-12-06-7859]). Due to these properties, sevoflurane is suitable for patients undergoing cardiovascular surgery, as it can not only be applied for normal anesthesia but also meets the requirements of patients with poor cardiac function, large hemodynamic fluctuations and high demand for circulation stability, in addition to protecting the nervous system during CPB ([@b24-mmr-12-06-7859]).

Although the protective effects of sevoflurane on the brain have been extensively studied, the exact underlying mechanism has never been fully elucidated. Wang *et al* ([@b25-mmr-12-06-7859]) confirmed that sevoflurane can upregulate the expression of inflammatory genes at the transcriptional and translational level, repress the expression of adhesion molecules and pro-inflammatory factors, including tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6, inhibit the infiltration of neutrophils and macrophages and alleviate inflammatory damage to the nervous system

As these mechanisms are similar to those of the protective effects of TLR3 on the brain, the present study investigated whether sevoflurane protects the brain from CPB-induced inflammatory damage by activating the TLR3 signaling pathway. For this, a rat model of CPB, which closely resembles clinical CPB in humans ([@b26-mmr-12-06-7859]), was used to study the influence of 2.4% sevoflurane pre-conditioning on CPB-induced brain injury as well as the involvement of the TLR3 signaling pathway.

Materials and methods
=====================

Experimental devices
--------------------

The following devices were used: Anesthesia respirator (Draeger, Lübeck, Germany), TCI-III dual-channel target-controlled infusion pump (Wuhan Changfeng Medical Appliance Co., Ltd, Wuhan, China), patient monitor (Datex-Ohmeda, Helsinki, Finland), NSP5100-type activated clotting time analyzer (Medtronic Inc., Minneapolis, MN, USA), BT00-300 M constant current peristaltic pump (Baoding Longer Precision Pump Co., Ltd., Baoding, China), rat membrane oxygenator (Guangdong Kewei Medical Instrument Co. Ltd., Guangdong, China), 856-type blood gas analyzer (Bayer, Whippany, NJ, USA), high-speed refrigerated centrifuge (Hunan Xiangyi Laboratory Instrument Development Co., Ltd., Hunan, China), small animal ventilator (Jiangxi Province Bentley Anesthesia Breathing Equipment Co., Ltd.) and disposable intravenous trocar (16, 18, 20, 22, 23 and 24 G; BD Biosciences, Franklin Lakes, NJ, USA).

Drugs and reagents
------------------

The following drugs and reagents were used in the present study: Sevoflurane (Shanghai Hengrui Medicine Co., Ltd, Shanghai, China), 10% chloral hydrate (Qingdao Yulong Algae Co., Ltd., Qingdao, China) 5% sodium bicarbonate (Jiang Su Runyang Pharmaceutical Co., Ltd., Jiangsu, China), 20% mannitol (Baxter Healthcare Trading Co, Ltd., Shanghai, China), 6% hydroxyethyl starch (Beijing Fresenius-Kabi Pharmaceutical Co., Ltd., Beijing, China), heparin sodium (Tianjin Pharmaceutical Group Co., Ltd., Tianjin, China), soda-lime (England Molecular Products Limited Co., Ltd., Harlow, UK), 10% formalin (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China), Ponceau S (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China), rat TLR3 (cat. no. 1487-TR-050), TRIF (cat. no. ab101232), IL-6 (cat. no. D6050), interferon (IFN)-β (cat. no. 41410-1), S100-β (cat. no. DY5578) ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive test kit (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China).

Experimental animals and grouping
---------------------------------

A total of 64 adult male Sprague Dawley rats (age, 12 weeks), weighing 350--450 g were provided by the Shenyang Military Region General Hospital Laboratory Animal Center (Shenyang, China; lot no. 20120002). The rats were maintained in a temperature (25°C) and humidity (50%) controlled environment, under a 12 h light/dark cycle. The rats were sacrificed by cervical dislocation. The animal experiments were approved by the Animal Experiments Ethics Committee of the General Hospital of Shenyang Military Region (Shenyang, China). Animals were fasted with free access to water for 12 h prior to surgery.

The animals were randomly divided into three groups: The sham operation group (H group; n=8), the CPB group (C group; n=24) and the sevoflurane pre-conditioning group (S group; n=32).

Model preparation and treatment
-------------------------------

Rats were prepared for CPB by intraperitoneal injection with 10% chloral hydrate (300 mg/kg) for anesthesia. Photopic oral intubation was performed using a 16 G intravenous catheter, and animals were mechanically ventilated with a small animal ventilator (settings: Frequency, 60 beats/min; tidal volume, 3 ml/kg; inspiratory to expiratory ratio, 1:1.5) connected to a monitor to observe the heart rate, oxygen saturation and rectal temperature of the rats.

Hair was removed at the puncture site, followed by disinfection, skin incision as well as isolation, exposure and puncture of the vascular vein. Left femoral vein catheterization (23G) was performed to open the fluid path, which was and connected to a micro infusion pump. The left femoral artery was catheterized (24G) and connected to the monitor for real-time monitoring of blood pressure. The right internal jugular vein was catheterized into the right atrium using a homemade long-short drainage needle (16G) in order to drain blood for CPB. The right femoral artery was catheterized for fixed CPB perfusion. Between the two puncture sites with the drainage tube, a homemade blood storage device, a constant peristaltic pump (Baoding Longer Precision Pump Co., Ltd.), silicone tubing (internal diameter, 4 mm) and a rat membrane oxygenator (Guangdong Kewei Medical Instrument Co. Ltd.) were installed to establish the CPB circuit. The left femoral vein was selected as the systemic heparin site in the rats, and heparin sodium (300 IU/kg) was injected when the activated clotting time reached 400--500 sec. Rats were pre-charged without blood to establish the without-blood pre-charge and the non-arrest charge CPB model in rats.

CPB was then performed using the membrane oxygenator to immediately supply oxygen. The low-flow CPB velocity was 35 ml/kg/min, which was later increased to 100--120 ml/kg/min at full-flow bypass. To prevent the formation of air embolism, 1--2 ml of blood was retained in the blood storage device whenever possible. The mean arterial pressure (MAP) was maintained at \>60 mmHg, the pH was kept at 7.35--7.45, the partial CO~2~ pressure (PaCO~2~) was kept at at 35--45 mmHg and hematocrit (Hct) was maintained at \>0.25. Rats were provided with epinephrine hydrochloride (2--20 *µ*g/100 g; Wuhan Grand Pharmaceutical Group Co., Ltd., Wuhan, China) and fluids intraoperatively in order to maintain a stable circulation.

Treatment of experimental groups
--------------------------------

In the H group, intubation and mechanical ventilation was performed in the right femoral artery only and the right internal jugular vein was catheterized without bypass. In the C group, the CPB model was established as described above. On the S group, 2.4% sevoflurane pre-conditioning was performed for 1 h prior to establishing the CPB model.

In groups C and S, CPB was performed for 1 h. During sevoflurane pre-conditioning, soda lime was placed under the gauze. For pre-conditioning, a box with two outlet holes was used - one hole to connect to the anesthesia ventilator and the other one to connect to the gas collection of the monitor to real-time monitor the concentration of oxygen and sevoflurane. The temperature inside the box was maintained at 35--37°C, the sevoflurane concentration was adjusted to 2.4% and rats were pre-conditioned for 1 h.

Specimen collection and processing
----------------------------------

Arterial and venous blood samples were collected at the following time-points: Prior to CPB (T~0~), CPB for 30 min (T~1~), CPB for 1 h (T~2~), 1 h after CPB (T~3~), 2 h after CPB (T~4~) and 3 h after CPB (T~5~). In addition, at T~0~, T~1~, T~3~ and T~5~, eight rats from the S group and C group were sacrificed and their brain tissue was collected.

Brain tissue
------------

Rats were infused with 250--400 ml saline, and the systemic circulation system was flushed and perfused. The skull was opened, the whole brain was removed, placed on an ice sheet and divided into two halves by a median sagittal line. The hippocampus was isolated from the two halves and then stored at −80°C (left) and in 10% neutral formalin (right).

Venous blood serum and arterial blood gas
-----------------------------------------

Venous blood samples were collected by centrifugation (10,000 × g; 10 min), and serum was stored in a cryogenic refrigerator (−80°C). Blood samples from the left femoral artery were subjected to blood gas analysis (0.3 ml per run). An equivalent volume of 6% hydroxyethyl starch was intravenously injected after sampling.

Determination of S100-β, IL-6, IFN-β in the rat serum by ELISA assay
--------------------------------------------------------------------

The serum levels of *S100-β, IL-6, IFN-β* were determined according to the manufacturer\'s instructions of the ELISA kits. The optical density was measured at 450 nm using a microplate reader (ELX800; Bio-Tek Instruments, Inc., Winooski, VT, USA) and analyzed using Gen5 software (Biotek Instruments, Inc.).

Determination of TLR3 and TRIF in the rat hippocampus by ELISA
--------------------------------------------------------------

The hippocampus was weighed and ground with 10 volumes of phosphate-buffered saline (PBS), followed by centrifugation (10,000 × g, 15 min) and collection of the supernatant. The protein levels of TLR3 and TRIF were detected by ELISA according to the manufacturer\'s instructions.

Western blot analysis of protein levels of TLR3 in the rat hippocampus
----------------------------------------------------------------------

After weighing and grinding the hippocampus, radioimmunoprecipitation assay buffer (Beijing Soledad Bao Biological Technology Co., Ltd., Beijing, China) was added (1 ml/100 mg tissue) and then homogenized (IKA T10; IKA^®^-Werke GmbH & Co. KG, Staufen, Germany) and centrifuged (4°C, 12,000 × g, 15 min). The supernatant was collected and protein concentrations were determined using a Bicinchoninic Acid kit (Beijing Soledad Bao Biological Technology Co., Ltd.). Loading buffer was then added to the protein samples. The protein (80 *µ*g) was separated by 8% SDS-PAGE at 100 V for 10--20 min. The voltage was increased to 200 V when the indicator entered the separation gel, and electrophoresis was continued for another 30--40 min. The blot was then electrophoretically transferred onto a nitrocellulose membrane and blocked with 5% non-fat milk in PBS with Tween 20 (PBST). The membrane was incubated with the rabbit anti-TLR3 polyclonal antibody (1:600 dilution; cat. no. PL031444R; Beijing Biosynthesis Biological Technology Co., Ltd., Beijing, China) and goat polyclonal β-actin antibody (1:500 dilution; cat. no. ab8229) at 4°C overnight, washed with TBST five times and then incubated with the horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Alexa Fluor^®^ 488; cat. no. ab175735; 1:5,000; Beijing Biosynthesis Biological Technology Co., Ltd.). The membrane was visualized using an Enhanced Chemiluminescence kit (Beijing Biosynthesis Biological Technology Co., Ltd.). Images were analyzed using Quantity One version 4.62 software (Bio-Rad Laboratories, Hercules, CA, USA), and expression of the target protein was normalized to β-actin.

In situ detection of apoptosis of hippocampal neurons by TUNEL assay
--------------------------------------------------------------------

Paraffin (Sinopharm Chemical Reagent Co., Ltd.) sections of hippocampal tissue were de-paraffinized and re-hydrated, digested with proteinase K solution for 15 min and washed four times with water. Sections were then incubated with H~2~O~2~-PBS buffer at room temperature for 15 min and washed with PBS three times for 5 min each. Samples were incubated with PBS containing TUNEL stain (KGI Nanjing Biotechnology Development Co., Ltd., Nanjing, China) for 60 min and with stop buffer for 30 min, followed by washing with PBS. Sections were incubated with horseradish peroxidase for 30 min, washed with PBS and then incubated with diaminobenzidine-H~2~O~2~ for 3 min. Following washing with PBS, samples were stained with methyl green for 10 min, and washed with distilled water and n-butanol three times each for, 1 min. Samples were dehydrated with xylene (Sinopharm Chemical Reagent Co., Ltd.) three times, dried and mounted. Normal neuronal nuclei were identified by a blue stain by hematoxylin (Sinopharm Chemical Reagent Co., Ltd.), defining them as negative for apoptosis. Damaged neuronal nuclei were identified by a brown stain, which indicated DNA breakage, defining them as positive for apoptosis. Fixed slices from each group were randomly selected from which five fields of view were randomly selected to capture images at high-power magnification (×400). The average integrated optical density values of damaged neurons were determined with a microscopic image analysis system (BX41; Olympus Corporation, Tokyo, Japan).

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 19.0 statistical software (International Business Machines, Armonk, NY, USA). Values are expressed as the mean ± standard deviation. Comparisons between groups were performed using one-way analysis of variance, and comparisons within a group were analyzed with repeated measures analysis of variance. P\<0.05 was considered to indicate a statistically significant difference between values.

Results
=======

Blood gas analysis and clinical parameters during CPB
-----------------------------------------------------

The MAP, heart rate (HR), Hct, rectal temperature, pH value, PaCO~2~, PaO~2~, base excess (BE) value and K^+^ at the indicated times in the three groups of rats show no statistically significant differences (P\>0.05). The MAP and HR were significantly decreased during CPB (compared to T~0~; P\<0.05), while after CPB, a gradual recovery was shown (compared to T~0~; P\>0.05). The Hct value was significantly decreased during CPB (P\<0.05), while the pH, Hct, PaCO~2~, PaO~2~, BE and K^+^ levels exhibited no statistically significant differences at different time-point within the groups (compared to T~0~; P\>0.05), [Table I](#tI-mmr-12-06-7859){ref-type="table"}.

Sevoflurane-pre-conditioning attenuates CPB-induced increases in serum levels of S100-β and IL-6
------------------------------------------------------------------------------------------------

The serum concentration of S100-β and IL-6 in the C group was significantly increased during and after CPB at T~1~--T~5~ (P\<0.05). Of note, the S100-β and IL-6 concentration in the S group was significantly lower than that in the C group (P\<0.05) indicating that pre-treatment with sevofluorane attenuated the CPB-induced increases in S100-β and IL-6 ([Tables II](#tII-mmr-12-06-7859){ref-type="table"} and [III](#tIII-mmr-12-06-7859){ref-type="table"}; [Figs. 1](#f1-mmr-12-06-7859){ref-type="fig"} and [2](#f2-mmr-12-06-7859){ref-type="fig"}).

Sevoflurane-pre-conditioning aggravates CPB-induced increases in serum levels of IFN-β as well as hippocampal levels of TLR3 and TRIF
-------------------------------------------------------------------------------------------------------------------------------------

The serum concentration of IFN-β as well as hippocampal levels of TLR3 and TRIF in the C group were significantly increased during and after CPB at T~1~--T~5~ (P\<0.05). Of note, IFN-β, TLR3 and TRIF levels in the S group were significantly increased compared with those in the C group (P\<0.05), indicating that pre-treatment with sevofluorane aggravated the CPB-induced increases IFN-β, TLR3 and TRIF ([Tables IV](#tIV-mmr-12-06-7859){ref-type="table"}--[](#tV-mmr-12-06-7859){ref-type="table"}[VI](#tVI-mmr-12-06-7859){ref-type="table"}; [Figs. 3](#f3-mmr-12-06-7859){ref-type="fig"}[](#f4-mmr-12-06-7859){ref-type="fig"}[](#f5-mmr-12-06-7859){ref-type="fig"}[](#f6-mmr-12-06-7859){ref-type="fig"}--[7](#f7-mmr-12-06-7859){ref-type="fig"})

Sevoflurane-pre-conditioning reduces CPB-induced apoptosis of hippocampal neurons
---------------------------------------------------------------------------------

The results of the TUNEL assay showed that the number of apoptotic hippocampal neuron cells was extremely low. However, in the C and S groups, the number of apoptotic hippocampal neurons was significantly higher than that in the H group (P\<0.05). Of note, the number of apoptotic cells was significantly reduced in the S group as compared to that in the C group, indicating that sevoflurane had a protective effect on hippocampal neurons during and following CPB ([Figs. 8](#f8-mmr-12-06-7859){ref-type="fig"} and [9](#f9-mmr-12-06-7859){ref-type="fig"}).

Discussion
==========

Impact of sevoflurane pre-conditioning on brain injury during CPB
-----------------------------------------------------------------

Sevoflurane is commonly used as an anesthetic in the clinic at a concentration of 1 minimum alveolar concentration (MAC) ([@b27-mmr-12-06-7859],[@b28-mmr-12-06-7859]), and 2.4% sevoflurane is equivalent to 1 MAC sevoflurane in rats. Hu *et al* ([@b29-mmr-12-06-7859]) found that after pre-conditioning with 2.4% sevoflurane for 1 h, ischemia-re-perfusion-induced brain injury was reduced. The rat middle cerebral artery occlusion model is used in current studies on brain injury, but sevoflurane has rarely been used in rat models of CPB. To better simulate clinical CPB and referring to preliminary studies by our group, 2.4% sevoflurane pre-conditioning of rats for 1 h was selected prior to establishing the CPB model.

S100-β is a sensitive and neuron-specific protein, which is lowly expressed in normal brain tissue. Only when brain tissue is damaged, cell and blood-brain barrier permeability increase, S100-β is activated and then immediately expressed, released into the cerebrospinal fluid and passes through the blood-brain barrier; therefore, S100-β levels in the peripheral blood effectively reflect the early extent of brain damage ([@b30-mmr-12-06-7859]).

Accordingly, in studies on CPB-induced brain injury, S100-β protein is utilized as a specific marker of early brain injury ([@b31-mmr-12-06-7859],[@b32-mmr-12-06-7859]). Singh *et al* ([@b33-mmr-12-06-7859]) examined the effects of sevoflurane and isoflurane anesthesia as well as total intravenous anesthesia on patients undergoing coronary artery bypass grafting and found that the protein levels of S100-β increased rapidly after CPB. Of note, sevoflurane was able to reduce the serum levels of S100-β in the patients. In the present study, the levels of S100-β were close to normal prior to CPB. During the CPB, S100-β levels in the H group remained low, indicating that simple puncture did not cause any significant brain damage. Compared with that in the H group, the S100-β concentration in the C and S groups significantly increased during CPB and remained at elevated levels after CPB, indicating that CPB caused brain injury in rats.

In the present study, TUNEL staining was performed to detect cell apoptosis. Compared to that in the H group, cell apoptosis was significantly increased in the C and S groups. Of note, sevoflurane pre-conditioning significantly reduced S100-β levels and the number of apoptotic hippocampal neurons at each time-point compared with those in the C group. These results suggested that CPB caused brain damage and apoptosis of hippocampal neurons, while sevoflurane pre-conditioning had a protective effect as indicated by decreased levels of serum S100-β and apoptotic hippocampal neurons.

Sevoflurane pre-conditioning alleviates brain damage through reducing the CPB-induced inflammatory response
-----------------------------------------------------------------------------------------------------------

Various factors during CPB can cause the release of a large number of lymphocytes and other pro-inflammatory cytokines as well as the development of systemic inflammatory response syndrome ([@b34-mmr-12-06-7859]). These factors include non-physiological perfusion or reduced local oxygen supply, which can be caused by insufficient blood supply, resulting in great damage to the brain. Recent studies have shown that inflammation is an important cause of cognitive dysfunction after CPB ([@b35-mmr-12-06-7859],[@b36-mmr-12-06-7859]); therefore, the focus of the present study was on how to positively and effectively reduce inflammation-induced damage during CPB.

IPC can enhance the brain\'s tolerance to traumatic effects of ischemia and hypoxia through pre-experimental cerebral ischemia ([@b37-mmr-12-06-7859]). The inflammatory reaction is an important cause of brain damage and inflammation may synergistically aggravate hypoxic-ischemic brain damage ([@b38-mmr-12-06-7859]). A study showed that prevention of inflammation can enhance the protective effect of IPC against cerebral ischemia, as IPC alleviates the extent of ischemia by decreasing the expression of pro-inflammatory genes and reducing neutrophil and macrophage infiltration in the ischemic area of infiltration ([@b4-mmr-12-06-7859]).

In a study on patients with coronary artery bypass and valve replacement, Ramlawi *et al* ([@b39-mmr-12-06-7859]) found that in the early post-operative stage, serum levels of IL-1 are significantly increased in patients with cognitive decline, and that the amount of cognitive decline is IL-1 concentration-dependent.

Ashraf *et al* ([@b40-mmr-12-06-7859]) found that during CPB, S100-β protein levels positively correlated with IL-6 expression levels, while expression of IL-6 promoted the protein levels of S100-β as well as the participation of inflammatory mediators and exacerbated brain damage.

Vila *et al* ([@b41-mmr-12-06-7859]) showed that IL-6 is closely associated with the area of acute cerebral infarction. The serum concentration of IL-6 was in parallel with the size of the cerebral infarction area, an independent risk factor of brain damage. The possible mechanisms is the promotion of aggregation and adhesion of inflammatory cells, partial infarction of brain tissue, activation of matrix metalloproteinases, destruction of the blood-brain barrier, stimulation of platelet activity, promotion of fibrinogen production and reduction of cerebral perfusion ([@b42-mmr-12-06-7859]--[@b45-mmr-12-06-7859]).

Bedirli *et al* ([@b46-mmr-12-06-7859]) found that sevoflurane pre-conditioning reduced ischemia-reperfusion-induced levels of inflammatory cytokines (TNF-α and IL-1β), thus reducing the inflammatory reaction caused by brain damage and thereby protecting the brain.

The present study found that the concentration of IL-6 in the CPB group was significantly higher than that in Group H during CPB and largely remained at a high level, indicating that inflammation occurs during CPB. Compared with those in the C group, the levels of IL-6 in the S group were significantly lower at each time-point. These results suggested that sevoflurane pre-conditioning alleviated the inflammatory response during CPB and exerted a protective effect on the brain through inhibiting the expression of the inflammatory cytokine IL-6.

The TLR3 signaling pathway is involved in the protective effect of sevoflurane on the brain during CPB
------------------------------------------------------------------------------------------------------

Previous studies found that pre-excited TLRs suppress brain inflammation and thus alleviate the effects of brain injury ([@b7-mmr-12-06-7859],[@b8-mmr-12-06-7859]). TLRs are innate immunity receptors widely expressed in the central nervous system, and TLR1-9 are expressed in primary cultured human microglia cells. The TLR family is involved in two signaling pathways: The MyD88-dependent pathway and the TRIF-dependent pathway. TLRs (except TLR3) increase the synthesis and release of pro-inflammatory cytokines by combining with the downstream protein MyD88 via the MyD88-dependent pathway. In the TRIF-dependent pathway, TLR3 and TLR4 are involved in type I interferon signaling to increase the expression of anti-inflammatory cytokines such as IFN-β.

The TLR3 pathway is the only solely TRIF-dependent pathway amongst all TLR pathways. TLR3 is expressed throughout the central nervous system and is highly expressed in astrocytes; TLR3 is particularly sensitive to cell damage ([@b47-mmr-12-06-7859]). TLRs are involved in the brain damage response to ischemia caused by inflammation through which they are activated to alleviate inflammation, and are pre-stimulated to provide a powerful neuroprotective effect ([@b48-mmr-12-06-7859]). Pan *et al* ([@b11-mmr-12-06-7859]) stimulated the expression of TLR3 by using the TLR3 agonist polyinosinic polycytidylic acid, which inhibited the release of pro-inflammatory cytokines as well as the expression of nuclear factor (NF)-κB and IL-6, and mitigated nerve cell damage.

In the present study, the TLR3 levels in the C group were significantly increased with the onset of CPB as compared with those in the H group, indicating CPB activated the expression n of TLR3 expression. Compared to those in the CPB group, the expression levels of TLR3 were significantly elevated in the S group even at T~0~ prior to CPB, which may be due to sevoflurane-induced pre-activated expression of the TLR3. During and after CPB, the levels of TLR3 in the S group were significantly higher than those in the C group, indicating that sevoflurane pre-conditioning up-regulated the expression of TLR3, thereby exerting a protective effect on the brain and reducing brain damage in rats caused by CPB.

TLR3 signaling pathways associated with the neuroprotective effect of sevoflurane pre-conditioning
--------------------------------------------------------------------------------------------------

When the body is subjected to external pathogen invasion, TLR3 combines with the pathogen through the TRIF-dependent pathway, activating the expression of downstream anti-inflammatory cytokines, including IFN-β, inhibiting the expression of pro-inflammatory cytokines, such as IL-6, and alleviating inflammation. TLR3 signaling is transduced exclusively through the TRIF pathway; thus, activating the expression of TLR3 may help to restore the balance between pro-inflammatory and anti-inflammatory cytokines following CPB, resulting in neuroprotection.

Previous studies suggested that pre-treatment with lipo-polysaccharide (LPS) or de-regulation of TRIF expression through IPC, ultimately increasing the release of anti-inflammatory cytokines, inhibits the release of pro-inflammatory cytokines mediated by NF-κB, thus protecting the brain ([@b6-mmr-12-06-7859],[@b8-mmr-12-06-7859]) Nhu *et al* ([@b49-mmr-12-06-7859]) found that LPS pre-treatment can upregulate TLR3 expression, thereby increasing the expression of downstream proteins of the TRIF pathway.

In the present study, it was observed that TLR3, TRIF and IFN-β expression levels were elevated in the C group, showing the same tendency as S100-β protein. After sevoflurane preconditioning, the expression levels of TLR3 and TRIF, IFN-β were further increased, while the expression of the pro-inflammatory cytokine IL-6 and the brain damage marker S100-β was decreased. The TLR3 signaling pathway may be pre-activated by sevoflurane, increasing the expression levels of TLR3 and its downstream signaling molecule TRIF prior to as well as during CPB to exert their protective effects against brain damage.

The present study generated a rat model of CPB and observed that sevoflurane pre-conditioning had a protective role on the brain to reduce CPB-induced damage. This protective role may be associated with the TLR3 signaling pathway, providing a novel target to prevent brain damage and improve the outcomes of clinical CPB. The findings of the present study can be concluded as follows: i) Sevoflurane pre-treatment has a protective effect against CPB-induced brain injury; ii) sevoflurane pre-treatment alleviates cerebral injury caused by a CPB-induced inflammatory reaction, through affecting the TLR3 signaling pathway; and iii) TLR3 signaling pathways involved in the neuroprotective effects of sevoflurane include the pre-activation of TLR3, up-regulation of the downstream TRIF, inhibition of the expression of pro-inflammatory cytokines IL-6 and upregulation of the anti-inflammatory factor IFN-β.

Further in-depth studies are required to explore the downstream mechanisms of TLR3-associated brain protection by sevoflurane. In addition, it should be attempted to discover the role of the each TLR and their cross-protective mechanisms in order to ultimately provide a theoretical support for the effects of cardiovascular surgeries on the brain as well as strategies to prevent brain damage.

The present study was supported by the Liaoning Natural Science Foundation (grant no. 20102244).
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![Serum levels of IL-6 in the experimental groups at various time-points. Values are expressed as the mean ± standard deviation. ^\#^P\<0.05 compared with T~0~; ^\*^P\<0.05 compared to H group; ^Δ^P\<0.05 compared with H group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; IL, interleukin.](MMR-12-06-7859-g01){#f2-mmr-12-06-7859}

![Concentration of IFN-β in the experimental groups at various time-points. Values are expressed as the mean ± standard deviation. ^\#^P\<0.05 compared with T~0~; ^\*^P\<0.05 compared to H group; ^Δ^P\<0.05 compared with C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; IFN, interferon.](MMR-12-06-7859-g02){#f3-mmr-12-06-7859}

![TLR3 protein levels in rat hippocampi in the experimental groups at various time-points. Values are expressed as the mean ± standard deviation. \#P\<0.05 compared with T~0~; ^\*^P\<0.05 compared to H group; ^Δ^P\<0.05 compared with C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; TLR, Toll-like receptor.](MMR-12-06-7859-g03){#f4-mmr-12-06-7859}

![TRIF protein levels in rat hippocampi in the experimental groups at various time-points. Values are expressed as the mean ± standard deviation. \#P\<0.05 compared with T~0~; ^\*^P\<0.05 compared to H group; ^Δ^P\<0.05 compared with H group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; TRIF, TIR-domain-containing adapter-inducing interferon-β.](MMR-12-06-7859-g04){#f5-mmr-12-06-7859}

![Western blot analysis of TLR3 expression levels in rat hippocampi. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group at T5.](MMR-12-06-7859-g05){#f6-mmr-12-06-7859}

![Relative expression levels of TLR3 in rat hippocampi determined by western blot analysis. Values are expressed as the mean ± standard deviation. ^\*^P\<0.05 compared with H group; ^Δ^P\<0.05 compared with C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group.](MMR-12-06-7859-g06){#f7-mmr-12-06-7859}

![Apoptosis of hippocampal neurons as indicated by terminal deoxynucleotidyl transferase dUTP nick end labeling in (A) H group, (B) C group and (C) S group (magnification, ×400). H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group.](MMR-12-06-7859-g07){#f8-mmr-12-06-7859}

![Integrated Optical Density Average value of positive hippocampal neuronal cells in each group. Values are expressed as the mean ± standard deviation. ^\*^P\<0.05 compared with H group; ^Δ^P\<0.05 compared with C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group.](MMR-12-06-7859-g08){#f9-mmr-12-06-7859}

###### 

Clinical parameters and blood gas analysis at various time-points.

  Project          T~0~           T~1~                                                         T~2~                                                        T~3~                                                       T~4~                                                       T~5~
  ---------------- -------------- ------------------------------------------------------------ ----------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  MAP (mmHg)       105.81±11.67   79.46±7.21[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}     73.66±5.28[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}    96.54±6.11                                                 93.25±8.04                                                 103.74±8.23
  HR (/min)        309.70±13.84   289.49±12.02[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}   290.50±9.74[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}   300.03±11.34                                               303.69±9.86                                                311.35±9.24
  RT (°C)          36.96±0.33     34.42±0.26                                                   35.22±0.33                                                  36.61±0.32                                                 36.85±0.27                                                 36.87±0.41
  pH               7.40±0.03      7.37±0.02                                                    7.37±0.02                                                   7.38±0.02                                                  7.39±0.03                                                  7.39±0.03
  PaCO~2~ (mmHg)   38.34±2.63     39.27±3.22                                                   39.32±4.01                                                  40.22±2.79                                                 39.64±2.51                                                 40.75±3.03
  PaO~2~ (mmHg)    322.28±21.35   309.52±14.39                                                 307.47±19.38                                                301.52±10.83                                               311.29±17.85                                               309.02±15.63
  BE (mmol/l)      −1.3±0.53      −2.5±0.63                                                    −2.3±0.37                                                   −2.2±0.45                                                  −1.3±0.25                                                  −2.5±0.34
  Hct              38.68±3.48     29.83±2.66[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}     30.13±2.19[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}    34.62±3.07[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}   33.24±2.75[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}   32.56±2.81[a](#tfn2-mmr-12-06-7859){ref-type="table-fn"}
  K^+^ (mmol/l)    4.27±0.39      4.30±0.38                                                    4.25±0.82                                                   4.17±0.40                                                  4.31±0.42                                                  4.33±0.37

Values are expressed as the mean ± standard deviation.

P\<0.05 compared with T~0~. T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; MAP, mean arterial pressure, HR, heart rate; RT, rectal temperature; Pa, partial pressure; BE, base excess; Hct, hematocrit.

###### 

S100-β levels in the experimental groups at various time-points.

  Group     T~0~        T~1~                                                                                                       T~2~                                                                                                       T~3~                                                                                                       T~4~                                                                                                       T~5~
  --------- ----------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  H group   7.21±0.76   7.39±0.80                                                                                                  7.14±0.78                                                                                                  7.19±0.80                                                                                                  7.32±0.79                                                                                                  7.10±0.79
  C group   7.58±0.68   15.79±1.33[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    15.12±1.34[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    14.21±1.32[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    15.21±1.41[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    15.79±1.43[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}
  S group   7.19±0.82   14.28±1.32[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   13.12±1.34[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   11.35±1.43[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   12.12±1.41[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   13.53±1.42[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation.

P\<0.05 compared to H group;

P\<0.05 compared to T~0~ group;

P\<0.05 compared to H group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass.

###### 

Serum levels of IL-6 in the experimental groups at various time-points.

  Group     T~0~        T~1~                                                                                                       T~2~                                                                                                       T~3~                                                                                                       T~4~                                                                                                       T~5~
  --------- ----------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  H group   9.60±0.85   9.53±0.76                                                                                                  9.47±0.85                                                                                                  9.57±0.72                                                                                                  9.51±0.71                                                                                                  9.79±0.68
  C group   9.77±0.61   12.53±1.07[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    11.99±1.09[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    11.67±1.10[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    11.37±0.99[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}    11.76±1.08[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn5-mmr-12-06-7859){ref-type="table-fn"}
  S group   9.69±0.80   11.68±1.20[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   10.06±1.12[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   10.62±1.00[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   10.58±0.91[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}   10.16±0.94[a](#tfn4-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn6-mmr-12-06-7859){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation.

P\<0.05 compared to H group;

P\<0.05 compared to T~0~ group;

P\<0.05 compared to H group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; IL, interleukin.

###### 

Serum levels of IFN-β in the experimental groups at various time-points.

  Group     T~0~           T~1~                                                                                                           T~2~                                                                                                           T~3~                                                                                                           T~4~                                                                                                           T~5~
  --------- -------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  H group   156.55±13.82   160.02±13.68                                                                                                   156.45±14.59                                                                                                   160.02±13.98                                                                                                   152.20±14.87                                                                                                   157.59±13.59
  C group   156.41±14.06   221.26±18.66[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn13-mmr-12-06-7859){ref-type="table-fn"}    202.29±17.29[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn13-mmr-12-06-7859){ref-type="table-fn"}    188.79±16.84[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn13-mmr-12-06-7859){ref-type="table-fn"}    198.69±17.13[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn13-mmr-12-06-7859){ref-type="table-fn"}    190.95±16.39[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn13-mmr-12-06-7859){ref-type="table-fn"}
  S group   160.71±14.03   252.26±19.74[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn14-mmr-12-06-7859){ref-type="table-fn"}   248.66±18.38[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn14-mmr-12-06-7859){ref-type="table-fn"}   232.45±18.06[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn14-mmr-12-06-7859){ref-type="table-fn"}   235.98±18.45[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn14-mmr-12-06-7859){ref-type="table-fn"}   236.55±18.58[a](#tfn12-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn14-mmr-12-06-7859){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation.

P\<0.05, compared with the H group;

P\<0.05, compared with the T~0~ group;

P\<0.05, compared with the C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; IFN, interferon.

###### 

TLR3 expression levels rat hippocampi in the experimental groups at various time-points.

  Group     T~0~                                                                                                       T~1~                                                                                                        T~3~                                                                                                        T~5~
  --------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  H group   5.01±0.53                                                                                                  5.21±0.53                                                                                                   4.58±0.48                                                                                                   5.11±0.45
  C group   5.08±0.51                                                                                                  7.14±0.67[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn17-mmr-12-06-7859){ref-type="table-fn"}    7.61±0.69[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn17-mmr-12-06-7859){ref-type="table-fn"}    7.38±0.55[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn17-mmr-12-06-7859){ref-type="table-fn"}
  S group   6.35±0.60[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"},[c](#tfn18-mmr-12-06-7859){ref-type="table-fn"}   8.73±0.72[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn18-mmr-12-06-7859){ref-type="table-fn"}   8.60±0.80[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn18-mmr-12-06-7859){ref-type="table-fn"}   8.54±0.78[a](#tfn16-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn18-mmr-12-06-7859){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation.

P\<0.05 compared to H group;

P\<0.05 compared to T~0~ group;

P\<0.05 compared to C group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; TLR, Toll-like receptor.

###### 

TRIF expression levels in rat hippocampi in the experimental groups at various time-points.

  Group     T~0~                                                                                                        T~1~                                                                                                         T~3~                                                                                                         T~5~
  --------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------
  H group   5.84±0.46                                                                                                   5.66±0.48                                                                                                    5.24±0.54                                                                                                    5.76±0.55
  C group   6.04±0.11                                                                                                   28.42±0.22[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn21-mmr-12-06-7859){ref-type="table-fn"}    24.59±0.34[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn21-mmr-12-06-7859){ref-type="table-fn"}    29.40±0.31[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"},[b](#tfn21-mmr-12-06-7859){ref-type="table-fn"}
  S group   25.48±0.29[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"},[c](#tfn22-mmr-12-06-7859){ref-type="table-fn"}   36.49±0.33[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn22-mmr-12-06-7859){ref-type="table-fn"}   34.53±0.25[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn22-mmr-12-06-7859){ref-type="table-fn"}   35.53±0.27[a](#tfn20-mmr-12-06-7859){ref-type="table-fn"}--[c](#tfn22-mmr-12-06-7859){ref-type="table-fn"}

Values are expressed as the mean ± standard deviation.

P\<0.05 compared to H group;

P\<0.05 compared to T~0~ group;

P\<0.05 compared to H group. H, sham group; C, CPB group; S, sevoflurane-pre-conditioned group; T~0~, prior to CPB; T~1~, CPB for 30 min; T~2~, CPB for 1 h; T~3~, 1 h after 1-h CPB; T~4~, 2 h after 1-h CPB; T~5~, 3 h after 1-h CPB; CPB, cardiopulmonary bypass; TRIF, TIR-domain-containing adapter-inducing interferon-β.
